Clearside Biomedical Inc. is using intraocular microneedles to deliver drugs directly to the back of the eye less invasively than intravitreal or subretinal injection. The approach lets Clearside use less drug than topical or periocular approaches and reduce side effects by minimizing off-target drug exposure.

Current drugs for back-of-the-eye disorders are hindered by poor delivery. Topical, periocular and systemic delivery expose many non-target tissues to drugs. So do invasive procedures such as ocular implants and intravitreal injection, the latter of which may cause vitreous hemorrhage, retinal detachment or endophthalmitis.